This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care.
The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.
At least 18 years of age at the time of cemiplimab treatment initiation
Has been diagnosed with histologically or cytologically documented squamous or non-squamous NSCLC
Prescribed a cemiplimab-based regimen as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the Summary of Product Characteristics (SmPC).
Can understand and complete the study-related questionnaires
Has received cemiplimab prior to enrollment
Has uncontrolled autoimmune disease
Has a contraindication to cemiplimab as noted in the local SmPC
Is concurrently participating in any other study of an investigational drug or procedure